Drugs / ACT-20-MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04398303 | May → Oct 2020 | pneumonia | Aspire Health Science | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-20-MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04398303 ↗ |
| Modality | Cell therapy | “allogenic human umbilical derived mesenchymal stem cells” NCT04398303 ↗ |
| Route | Intravenous | “ACT-20-MSC and ACT-20-CM administered intravenously” NCT04398303 ↗ |